Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pizuglanstat - Taiho Pharmaceutical

Next Previous
Drug Profile

Pizuglanstat - Taiho Pharmaceutical

Alternative Names: TAS-205

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Morpholines; Piperazines; Piperidines; Pyrroles; Small molecules
  • Mechanism of Action Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Duchenne muscular dystrophy

Most Recent Events

  • 18 Jun 2026 Taiho Pharmaceuticals completes the phase III REACH-DMD trial in Duchenne muscular dystrophy (In children, In adolescents, In adults, In the elderly) in Japan (PO) (NCT04587908)
  • 05 Feb 2026 TAS 205 is still in phase-III trials for Duchenne muscular dystrophy in Japan (Taiho Pharmaceutical pipeline, February 2026)
  • 27 Apr 2023 Pizuglanstat is still in phase III trials for Duchenne muscular dystrophy in Japan (Taiho Pharmaceuticals pipeline, April 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top